Best Nanotechnology Stocks To Follow Today – April 6th

OSI Systems, Biodexa Pharmaceuticals, NVE, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares in companies that focus on developing and commercializing products and services using nanotechnology—manipulating matter at an atomic and molecular scale. These companies often work on innovative solutions across various sectors, including medicine, electronics, and energy, offering high growth potential along with an inherent degree of risk due to the emerging nature of the technology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ:OSIS traded down $5.85 during trading on Friday, reaching $174.46. The stock had a trading volume of 358,210 shares, compared to its average volume of 178,425. OSI Systems has a 52 week low of $126.57 and a 52 week high of $220.00. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.25 and a current ratio of 1.88. The firm’s fifty day moving average is $197.46 and its 200 day moving average is $172.68. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of 22.45, a P/E/G ratio of 1.81 and a beta of 1.19.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of BDRX traded up $0.22 during trading hours on Friday, hitting $1.69. The stock had a trading volume of 15,941,543 shares, compared to its average volume of 569,506. The business’s 50 day moving average is $3.10. Biodexa Pharmaceuticals has a 1-year low of $1.14 and a 1-year high of $74.00.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVEC stock traded down $0.90 during midday trading on Friday, reaching $57.77. 40,931 shares of the company’s stock traded hands, compared to its average volume of 21,475. The firm’s fifty day moving average price is $68.46 and its 200-day moving average price is $75.29. NVE has a 52 week low of $56.11 and a 52 week high of $89.98. The company has a market cap of $279.43 million, a price-to-earnings ratio of 18.64 and a beta of 1.05.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN traded down $0.36 on Friday, reaching $2.69. The company’s stock had a trading volume of 34,169 shares, compared to its average volume of 78,969. The stock has a market capitalization of $23.12 million, a PE ratio of -0.51 and a beta of 0.46. Clene has a twelve month low of $2.57 and a twelve month high of $9.20. The firm has a fifty day moving average of $4.23 and a 200-day moving average of $4.73.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of VRPX stock traded down $0.32 on Friday, hitting $0.35. The stock had a trading volume of 148,800 shares, compared to its average volume of 198,943. Virpax Pharmaceuticals has a 12-month low of $0.13 and a 12-month high of $101.32. The business has a 50 day moving average of $5.01 and a 200 day moving average of $10.03.